{"id":"W4411037230","doi":"10.1038/s41591-025-03725-4","title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Jewish General Hospital","funders":"Genentech; Japanese Society of Medical Oncology; Eisai; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Natera; Les Laboratories Pierre Fabre; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; F. Hoffmann-La Roche; Vifor Pharma; Chugai Pharmaceutical; Seagen; OncoSec Medical; Roche; Amgen; Pfizer; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Atezolizumab; Breast cancer; Randomized controlled trial; Medicine; Stage (stratigraphy); Oncology; Triple-negative breast cancer; Perioperative; Internal medicine; Peri; Cancer; Surgery; Biology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003425871,0.000519724,0.001022578,0.0001226862,0.0001559102,0.0006273011,0.000356623,0.0005972818,0.001152872],"category_scores_gemma":[0.002431884,0.0001980435,0.00147969,0.000227934,0.0005017847,0.0003445486,0.000316004,0.001458071,0.0002129517],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004026762,"about_ca_system_score_gemma":0.0006975778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002655878,"about_ca_topic_score_gemma":0.001096806,"domain_scores_codex":[0.9989375,0.0007819628,0.0000494226,0.00007291687,0.00007390547,0.00008416389],"domain_scores_gemma":[0.9983466,0.0006231958,0.0005038423,0.0001560398,0.00008520063,0.0002850886],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.900454,0.004670286,0.01307667,0.0007292046,0.001991297,0.000103763,0.00009598051,0.001286376,0.008887351,0.0001747756,0.001448132,0.06708221],"study_design_scores_gemma":[0.6161847,0.3068936,0.05955788,0.0001474959,0.003982325,0.0004393046,0.00008553783,0.001629379,0.006637383,0.0005278476,0.003857588,0.00005694386],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925448,0.004207782,0.0006276026,0.0004362776,0.00009564115,0.0004354342,0.0006031835,0.00002476196,0.001024588],"genre_scores_gemma":[0.9949176,0.001265738,0.000942229,0.000605239,0.0001128577,0.0005718724,0.001003675,0.00001055611,0.0005701201],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003425871,"threshold_uncertainty_score":0.0181179,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03117827596201543,"score_gpt":0.4133979229228024,"score_spread":0.382219646960787,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}